NCT02012699 Integrated Cancer Repository for Cancer Research
| NCT ID | NCT02012699 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Nebraska |
| Condition | Pancreatic Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 999,999 participants |
| Start Date | 2013-11-01 |
| Primary Completion | 2099-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 999,999 participants in total. It began in 2013-11-01 with a primary completion date of 2099-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.
Eligibility Criteria
Inclusion Criteria * Diagnosis/history of cancer * Risk for developing cancer or suspicious clinical findings * No history of cancer (normal control registry) * Able to provide informed consent * 19 years of age or older * English or Spanish speaking individuals Exclusion Criteria * Unable to provide informed consent because of cognitive impairment * Non-English or non-Spanish speaking individuals
Contact & Investigator
Kurt Fisher, MD, PhD
PRINCIPAL INVESTIGATOR
University of Nebraska
Frequently Asked Questions
Who can join the NCT02012699 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 110 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02012699 currently recruiting?
Yes, NCT02012699 is actively recruiting participants. Contact the research team at kfisher@unmc.edu for enrollment information.
Where is the NCT02012699 trial being conducted?
This trial is being conducted at Greenwood Village, United States, Manchester, United States, Daytona Beach, United States, DeLand, United States and 11 additional locations.
Who is sponsoring the NCT02012699 clinical trial?
NCT02012699 is sponsored by University of Nebraska. The principal investigator is Kurt Fisher, MD, PhD at University of Nebraska. The trial plans to enroll 999,999 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.